Celltrion and Teva announced today that the FDA has accepted the companies’ Biologics License Application (BLA) for CT-P10, a proposed rituximab biosimilar. FDA regulatory action is expected in early 2018.
Celltrion and Teva announced today that the FDA has accepted the companies’ Biologics License Application (BLA) for CT-P10, a proposed rituximab biosimilar. FDA regulatory action is expected in early 2018.
The BLA includes efficacy, safety, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) data demonstrating the similarity of CT-P10 and the reference product (Rituxan, which is approved to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis). Trials were conducted in over 600 patients and include up to 104 weeks of data.
In February, the European Commission approved CT-P10, and the product has since launched in the United Kingdom, Germany, the Netherlands, and Spain, where the treatment is marketed under the names Tuxella, Ritemvia, Blitzima, and Truxima, respectively, for specific indications. CT-P10 is also available to patients in the Republic of Korea.
Woo Sung Kee, CEO of Celltrion, said in the companies’ announcement: “CT-P10…is continuing to build a solid track record since its [EU] launch earlier this year, and has provided patients with access to a high-quality treatment option and has offered great saving in healthcare costs. I am hopeful that CT-P10 will bring similar benefits to the United States when approved.”
In addition to providing such benefits to patients and health systems, Celltrion, along with its US commercial partner, Teva, certainly hopes to capture significant sales with its biosimilar of the world’s second highest-earning drug; Rituxan generated $7 billion in sales in 2016 alone.
News of Celltrion’s BLA comes just ahead of a planned initial public offering (IPO) for Celltrion Healthcare, the marketing affiliate of Celltrion Inc. The marketing company, which exclusively markets, sells, and distributes the biosimilar products produced by Celltrion, plans to sell 24.6 million shares in an effort to raise the equivalent of over $700 million. The IPO price will be set on or around July 17. Celltrion Healthcare’s representatives are reported as saying that the listing should help build direct sales networks for the biosimilar manufacturer’s products overseas as the South Korean drug maker seeks to make further inroads into lucrative biosimilars markets.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.